Studies the quality of sarcoma care across European and Latin American centers
Observes how sarcoma patients are diagnosed and treated, comparing expert and non-expert centers.
Plain-language title generated from the registry record
Registry title: Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK
Key facts
- Where
- São Paulo, BrazilSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 120 years old?
Source: NCT04181970, who can take part
Where in Brazil
- A.C. CamargoSão Paulo, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Grupo Espanol de Investigacion en Sarcomas
- Trial code
- NCT04181970
- Record updated
- 21 March 2025
- Original description
Post-authorisation, multicentric, observational, retrospective and prospective study to assess quality of care of sarcoma patients in expert and non-expert centers by analysing correlation of quality items and outcomes such as relapse free survival, overall survival, percentage of amputation, etc.Read full original descriptionShow less
Observational Study, for Quality Assessment, of Sarcoma As a Model to Improve Diagnosis and Clinical Care of Rare Tumors Through a European and Latin American Multidisciplinary NETWORK
Post-authorisation, multicentric, observational, retrospective and prospective study to assess quality of care of sarcoma patients in expert and non-expert centers by analysing correlation of quality items and outcomes such as relapse free survival, overall survival, percentage of amputation, etc.
Expert pathology peer review will be performed to detect differences between expert and non-expert centers as well as differences in treatment and patient prognosis.
Tumor samples of 4 types of sarcoma would also be included in translational research to detect biomarkers and produce preclinical models.
Inclusion: Histological diagnosis of soft-tissue sarcoma, GIST or bone sarcoma (all subtypes) from January 2005 until Juny/September 2023; ≥ 18 years; Available clinical and treatment information.
Exclusion: There is no exclusion criteria.